Expert neuropathologic consultation for complex brain, spinal cord, and peripheral nerve cases. We connect histopathology, molecular signatures, and clinical course, grounded in decades of academic leadership and bench-to-bedside research in glioma invasion and angiogenesis.
Contact UsLed by a board-certified neuropathologist who directs a neuro-oncology laboratory and has shaped modern understanding of glioma invasion, hypoxia response, and tumor vascular biology.
Board-Certified Neuropathologist | Division Chief | Director, Molecular Neuro-Oncology Laboratory
A nationally recognized neuropathologist with more than three decades at major academic medical centers, serving as professor of pathology and neurosurgery, division chief of neuropathology, and director of a molecular neuro-oncology laboratory. Licensed and dual-board certified in Anatomic Pathology and Neuropathology, with thousands of brain and spinal tumor specimens interpreted while mentoring residents, fellows, and junior faculty.
Research pioneered models of glioma invasion and angiogenesis, introduced the concept of vascular involution, and demonstrated how hypoxia-inducible pathways (HIF-1alpha/CXCR4) drive tumor spread. Co-developed predictive MR algorithms for low-grade gliomas and is repeatedly recognized for teaching and scholarship with national awards.
Medical license; American Board of Pathology certifications in Anatomic Pathology and Neuropathology.
Professor of Pathology and Neurosurgery; Chief of Neuropathology; long-standing neuropathologist at major academic medical centers.
Directs a molecular neuro-oncology laboratory focused on glioma angiogenesis, invasion, and hypoxia signaling, with extensive publication and editorial-board service.
Recipient of multiple teaching honors and national recognition for neuro-oncology scholarship.
Training. B.S. in mathematics and biology; M.D.; Ph.D. in neurology and neurosurgery; internship in general surgery; residency in anatomic pathology; fellowships in neuropathology and cell biology at leading academic medical centers.
Clear, defensible opinions for litigation, regulatory review, and complex clinical questions.
Comprehensive histopathology for gliomas, meningiomas, pituitary tumors, pediatric brain tumors, and metastatic disease with correlation to clinical and imaging findings.
Interpretation of hypoxia-inducible signaling (HIF-1alpha/CXCR4), angiogenic markers, and related molecular assays to clarify mechanisms of invasion and treatment response.
Evaluation of surgical margins, radiation/chemotherapy effect, anti-angiogenic therapy patterns, and progression versus pseudoprogression in high-grade gliomas.
Board-certified expert witness testimony, deposition support, and detailed reports that integrate pathology, molecular data, and peer-reviewed literature.
Consultative review of experimental models, including glioma invasion assays and angiogenesis studies, informed by decades of laboratory leadership.
Case-based teaching for legal teams and medical stakeholders, translating complex neuropathology into clear, courtroom-ready narratives.
Examples of the neuropathology issues we address for plaintiff and defense teams.
Engage board-certified neuropathology expertise that integrates histology, molecular drivers, and clinical context.